STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

Rhea-AI Summary
Kite, a Gilead Company (Nasdaq: GILD) has announced the results of four new analyses supporting the use of Tecartus® (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia (R/R B-ALL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
News

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Rhea-AI Summary
Kite, a Gilead Company (Nasdaq: GILD), announced the three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) as first-line treatment after chemoimmunotherapy in high-risk, large b-cell lymphoma (LBCL) patients. The results demonstrated an 86% complete response rate and an 81% three-year estimate for overall survival, indicating the potential of Yescarta as a first-line treatment option for high-risk LBCL patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
News

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) has been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year. The company was also included on the Dow Jones Sustainability North America Index (DJSI North America). These rankings are based on an in-depth analysis of Gilead’s sustainability performance, highlighting the company’s longstanding sustainable business practices and transparency on environmental, social, and governance (ESG) issues. Gilead’s ESG strategy aims to position the company as an employer of choice that delivers shareholder value in a sustainable, responsible manner. The company's focus on scientific innovation and sustainable business practices is centered around the needs of patients, employees, and communities around the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
News

Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

Rhea-AI Summary
Gilead Sciences, Inc. (NASDAQ:GILD) announced new data supporting the use of Trodelvy in metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients at the SABCS 2023. The data will be presented in eight abstracts, reinforcing Trodelvy's use in these difficult-to-treat breast cancers. Trodelvy is the first approved Trop-2-directed ADC to significantly improve survival in both mTNBC and pre-treated HR+/HER2- metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
-
News

Gilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt

Rhea-AI Summary
Gilead Sciences (GILD) employees collaborate to create a special panel of the AIDS Memorial Quilt, dedicated to honoring loved ones lost to HIV. The project involved over 100 volunteers and is a tribute to those impacted by HIV, with the panel displayed at various locations including the National AIDS Memorial in San Francisco and Mexico City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
News

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) to present new data at San Antonio Breast Cancer Symposium 2023 supporting the use of Trodelvy in certain metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
News

Gilead's Ambition: To Help End the HIV Epidemic

Rhea-AI Summary
Gilead Sciences, Inc. (GILD) aims to end the HIV epidemic globally through community partnerships and innovative medicines. The company collaborates with organizations like GNP+, UNAIDS, and PEPFAR to expand access to care in low- and middle-income countries. Gilead operates in over 35 countries and is headquartered in Foster City, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
News

Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas

Rhea-AI Summary
Gilead Sciences (GILD) Director of Community Health Access and Relations, Claudia Hardy, is working to bring cancer resources and preventive care to underserved communities in Alabama. As the director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Claudia's personal experience growing up in a medically underserved area and a food desert gives her a unique understanding of the barriers to cancer care in rural areas. She aims to address the lack of transportation, medical lingo comprehension, and access to comprehensive treatment in these communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
-
News

Kite and Arcellx Announce Expansion in Strategic Partnership

Rhea-AI Summary
Gilead (GILD) & Arcellx (ACLX) expand collaboration for CART-ddBCMA & ARC-SparX program ACLX-001. Kite exercises option to negotiate license for ARC-SparX program ACLX-001 in multiple myeloma. Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment. The collaboration aims to bring potentially best-in-class cell therapy to patients, expanding opportunities in lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
News

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, with Kite investing $200M at $61.68 per share and an $85 million upfront cash payment. Kite exercised its option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma and expanded the collaboration to include lymphomas. This investment is anticipated to extend Arcellx's cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

Nasdaq:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY